The first-in-class disease-modifying drug for chronic airway disorders

Project description

A novel disease-modifying drug for chronic obstructive pulmonary disease

Fields of science

• medical and health sciences › medical biotechnology › cells technologies › stem cells
• medical and health sciences › basic medicine › pharmacology and pharmacy › drug resistance › antibiotic resistance
• social sciences › sociology › demography › mortality
• social sciences › economics and business › business and management › commerce

Programme(s)

• H2020-EU.3. - PRIORITY 'Societal challenges
• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
• H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Topic(s)

• EIC-SMEInst-2018-2020 - SME instrument

Call for proposal

H2020-EIC-SMEInst-2018-2020-3
See other projects for this call

Funding Scheme

SME-2b - SME Instrument (grant only and blended finance)

Coordinator

EpiEndo Pharmaceuticals ehf

Address

Eidistorg 13-15, 3Rd Floor, Innovation House
170 Seltjarnarnes
Iceland

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU contribution

€ 2 500 000